Research Update

HSCI research inspires startup

November 16, 2016

Startup Magenta Therapeutics licences technologies from Harvard, MGH, and Boston Children's that could transform treatment of blood diseases and immune disorders

Harvard University has completed a license agreement with Magenta Therapeutics, a new startup company launched in Cambridge, for a portfolio of technologies with the potential to transform blood stem cell transplants from a “treatment of last resort” into a safer, more efficient therapy for patients with blood diseases and immune …

Targeted BMI1 inhibition impairs tumor growth lung adenocarcinomas with low CEBPα Expression

August 3, 2016

Researchers at the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS), in collaboration with Harvard Stem Cell Institute (HSCI), have discovered a new way in which the development of lung cancer can be stopped. In a study published in Science Translational Medicine, the researchers found that inhibiting a protein called BMI1 impaired tumour growth in lung cancer.